kras peptide vaccine
Vaccineexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2020 (NCT04117087)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- GTPase KRasImmunity, active
KRAS immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05254184 | Phase 1 | Nov 1, 2022 | Johns Hopkins University |
| NCT05013216 | Phase 1 | Dec 31, 2021 | Johns Hopkins University, Stand Up To Cancer |
| NCT04117087 | Phase 1 | Jan 31, 2020 | Bristol-Myers Squibb, Johns Hopkins University, National Cancer Institute (NCI), National Institutes of Health (NIH) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johns Hopkins University | Academic/Hospital | 3 | 3 | 1 | 2020 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2020 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2020 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2020 |
| Stand Up To Cancer | Academic/Hospital | 1 | 0 | 1 | 2021 |
5 organizations
Page 1 / 1